cannabidiol

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy; Analysts Reiterate Buy Ratings

An incredible amount of planning and preparation goes into the design of…

Robin Lefferts
October 27, 2026

Investor Opportunity: U.S. Government Focus on CBD as Medicine

The potential for federal cannabis rescheduling is rightly getting a lot of…

Wilson Augustine
December 23, 2025

A Close Look at Cardiol Therapeutics’ Phase 2 Results Shows the Path Forward

Not all clinical trial results are cut and dried. Sometimes the outcome…

Robin Lefferts
December 9, 2025

Cardiol Therapeutics Advancing Orphan Drug Trial to Phase 2/3

Clinical trials are crucial for smaller pharma companies. While the ultimate aim…

Robin Lefferts
October 28, 2024

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1…

Ryan Allway
October 22, 2024

The Impact of Positive Phase 2 Trial Results on a Smaller Company

A few weeks back, we covered the effect an Orphan Drug Designation…

Robin Lefferts
March 12, 2024

The Impact of Orphan Drug Development on a Smaller Company

Orphan drugs treat conditions with less than 200,000 patients annually in the…

Robin Lefferts
February 6, 2024

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Toronto, Ontario–(Newsfile Corp. – November 16, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

Ryan Allway
November 16, 2023

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

BERWYN, Pa., January 04, 2023–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:…

Ryan Allway
January 4, 2023

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)

–VRPX Intranasal Cannabidiol Product Candidate for Management of Epilepsy in Children and…

Ryan Allway
December 14, 2022

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy; Analysts Reiterate Buy Ratings

Investor Opportunity: U.S. Government Focus on CBD as Medicine

A Close Look at Cardiol Therapeutics’ Phase 2 Results Shows the Path Forward

Cardiol Therapeutics Advancing Orphan Drug Trial to Phase 2/3

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

The Impact of Positive Phase 2 Trial Results on a Smaller Company

The Impact of Orphan Drug Development on a Smaller Company

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)

Don Kreski

Robin Lefferts

Ryan Allway

Stella Emory

Wilson Augustine

MBody AI Doubles Deployment at Major Northeast Casino & Entertainment Destination

Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets

Graphite One Secures Final Ohio Air Permit, Supporting Further Progress towards Planned Construction for US$80 Million Phase 1 Anode Plant

Opportunity: The United States Still Needs A Lot of Domestic Lithium

Sign Up for Our Newsletter